Abstract
Prostate cancer remains the most common non-cutaneous malignancy among American men. Since the advent of PSA testing, most men are diagnosed with localized disease, but a proportion of men will be diagnosed with metastatic disease, many will eventually receive chemotherapy with docetaxel and prednisone. However, responses are not durable and all men will ultimately progress on this treatment. As such, continued efforts are geared towards the discovery of new agents and mechanisms of targeting prostate cancer. Angiogenesis has been shown to play an important role in tumorigenesis, proliferation and metastasis in prostate cancer. Here we discuss the major angiogenic signaling pathway involving VEGF in prostate cancer progression, and the role of various promising agents that targeting this pathway. This includes bevacizumab, thalidomide and its analogs, tyrosine kinase inhibitors sorafenib and AZD2171, and other inhibitors of angiogenic signaling pathways. Results of key clinical trials associated with the use of these agents and future directions are discussed herein.
Keywords: Angiogenesis, Prostate Cancer, Bevacizumab, Thalidomide, Lenalidomide, AZD2171, Sorafenib
Current Molecular Pharmacology
Title: VEGF Inhibitors and Prostate Cancer Therapy
Volume: 2
Author(s): Jeanny B. Aragon-Ching and William L. Dahut
Affiliation:
Keywords: Angiogenesis, Prostate Cancer, Bevacizumab, Thalidomide, Lenalidomide, AZD2171, Sorafenib
Abstract: Prostate cancer remains the most common non-cutaneous malignancy among American men. Since the advent of PSA testing, most men are diagnosed with localized disease, but a proportion of men will be diagnosed with metastatic disease, many will eventually receive chemotherapy with docetaxel and prednisone. However, responses are not durable and all men will ultimately progress on this treatment. As such, continued efforts are geared towards the discovery of new agents and mechanisms of targeting prostate cancer. Angiogenesis has been shown to play an important role in tumorigenesis, proliferation and metastasis in prostate cancer. Here we discuss the major angiogenic signaling pathway involving VEGF in prostate cancer progression, and the role of various promising agents that targeting this pathway. This includes bevacizumab, thalidomide and its analogs, tyrosine kinase inhibitors sorafenib and AZD2171, and other inhibitors of angiogenic signaling pathways. Results of key clinical trials associated with the use of these agents and future directions are discussed herein.
Export Options
About this article
Cite this article as:
Aragon-Ching B. Jeanny and Dahut L. William, VEGF Inhibitors and Prostate Cancer Therapy, Current Molecular Pharmacology 2009; 2 (2) . https://dx.doi.org/10.2174/1874467210902020161
DOI https://dx.doi.org/10.2174/1874467210902020161 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gold Nanoparticles; Potential Nanotheranostic Agent in Breast Cancer: A Comprehensive Review with Systematic Search Strategy
Current Drug Metabolism Exploring Cancer Therapeutics with Natural Products from African Medicinal Plants, Part I: Xanthones, Quinones, Steroids, Coumarins, Phenolics and other Classes of Compounds
Anti-Cancer Agents in Medicinal Chemistry Identification of Functional Peptides from Natural and Synthetic Products on Their Anticancer Activities by Tumor Targeting
Current Medicinal Chemistry CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Lipids as Activators of Innate Immunity in Peptide Vaccine Delivery
Current Medicinal Chemistry Involvement of MicroRNA Mir15a in Control of Human Ovarian Granulosa Cell Proliferation, Apoptosis, Steroidogenesis, and Response to FSH
MicroRNA DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Genetic Profile of SNP(s) and Ovulation Induction
Current Pharmaceutical Biotechnology Evolution of the Strategies for Screening and Identifying Human Tumor Antigens
Current Protein & Peptide Science Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools
Anti-Cancer Agents in Medicinal Chemistry Vitamin D Analogs in Cutaneous Malignancies
Current Pharmaceutical Design Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
Anti-Cancer Agents in Medicinal Chemistry Colony-Stimulating Factor-1 Receptor Inhibitors for the Treatment of Cancer and Inflammatory Disease
Current Topics in Medicinal Chemistry Pharmacological Exploitation of Indole-3-Carbinol to Develop Potent Antitumor Agents
Mini-Reviews in Medicinal Chemistry Guggulsterone for Chemoprevention of Cancer
Current Pharmaceutical Design Editorial: [Hot Topic: Non-Analgesic Effects of Opioids]
Current Pharmaceutical Design Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism Chelating Agents and their Use in Radiopharmaceutical Sciences
Mini-Reviews in Medicinal Chemistry The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy
Current Cancer Drug Targets